Solid Catalytic Kits for API Degradation Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The pharmaceutical industry faces challenges in predicting the stability and degradation of solid pharmaceutical ingredients due to the complexity of solid phase reactions, which are often time-consuming and lack reliable prediction tools, leading to delays in drug development.
Innovation Solution
A kit comprising containers with solid catalytically active compounds, such as sulfuric acid or chlorosulfonic acid absorbed on silica gel, KOH or NaOH absorbed on silica gel, and KMnO4 absorbed on silica gel, is used in a mechanochemical process to simulate and predict the transformation of APIs and excipients into degradation products in a shortened time span, minimizing experimental matrix and material usage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional solid phase reaction tests are used to predict stability, then reliable prediction can be achieved, but the process is highly time-consuming causing major delays
Solution Approach 1:
The patent applies parameter changes by modifying reaction conditions to accelerate degradation pathways. Specifically, it uses elevated temperatures (40-80°C), controlled humidity (40-80% RH), and catalytic promoters to speed up solid-phase reactions that would normally take months to years, enabling predictions within weeks while maintaining reliability through controlled stress conditions
Solution Approach 2:
The patent implements preliminary action by conducting forced degradation studies under accelerated stress conditions before actual product launch. This allows identification of potential degradation pathways and stability issues early in development, enabling proactive formulation adjustments rather than reactive problem-solving after problems manifest
2Reliability
If research-based approaches are used to understand solid phase reactions, then scientific understanding is improved, but the focus is not suitable to answer questions from a drug developmental point of view
Solution Approach 1:
The patent achieves universality by creating a multi-functional testing platform that simultaneously addresses multiple drug development questions. The same accelerated stability testing system can evaluate API stability, API-excipient compatibility, formulation shelf-life prediction, and packaging material interaction, replacing the need for separate specialized studies
Solution Approach 2:
The patent uses controlled stress conditions (temperature, humidity, catalytic agents) as intermediaries to simulate real-world storage and handling scenarios. These controlled stressors act as mediators that accelerate degradation pathways while maintaining relevance to actual product performance, bridging the gap between basic science and applied development
3Loss of information
If traditional stability testing is performed, then comprehensive data can be obtained, but the experimental setup is complex and not scalable
Solution Approach 1:
The patent applies segmentation by dividing the stability testing into modular components: separate stress condition protocols (temperature, humidity, catalytic), separate sample types (API alone, API-excipient mixture, formulation), and separate analysis methods. This modular approach enables systematic data collection while simplifying individual test components and facilitating scalability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for fast, reliable, and repeatable results in predicting stability, shelf-life, API-excipient compatibility, and degradation profiles, optimizing drug development with lower failure rates and reduced material consumption.
Implementation Method 1
Kits comprising containers with at least one solid catalytically active compound... for simulating and predicting the transformation of a compound... into the respective degradation product(s)
Implementation Method 2
catalyst that is 3-15% (w/w) sulfuric acid or chlorosulfonic acid absorbed on silica gel 60 (70-230 mesh)
Implementation Method 3
catalyst that is 3-15% (w/w) KMnO4 absorbed on silica gel or alox
Data Source
AI summary
Subject matter of the present invention are kits comprising containers with at least one solid catalytically active compound, their uses in processes for simulating and predicting the transformation of a compound that is preferably a solid active pharmaceutical ingredient (API), preferably an API in combination with an excipient, in a shortened time span, into the respective degradation product(s).